Blockbuster taps new indication

Posted 12 May 2025 PM

The TGA has followed MedSafe in expanding the use of Vertex’s Trikafta with an additional 45 Australians living with cystic fibrosis (CF) now eligible to receive the blockbuster triplet therapy.

On 8 May, the TGA expanded the approval to include to include patients aged two years and older who meet the diagnostic criteria for CF and who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive based on clinical or in vitro evidence.

To see the whole article, please login